PL3502105T3 - Postać polimorficzna związku stanowiącego inhibitor kinazy, zawierająca ją kompozycja farmaceutyczna oraz sposób jej wytwarzania i jej zastosowanie - Google Patents

Postać polimorficzna związku stanowiącego inhibitor kinazy, zawierająca ją kompozycja farmaceutyczna oraz sposób jej wytwarzania i jej zastosowanie

Info

Publication number
PL3502105T3
PL3502105T3 PL17855006T PL17855006T PL3502105T3 PL 3502105 T3 PL3502105 T3 PL 3502105T3 PL 17855006 T PL17855006 T PL 17855006T PL 17855006 T PL17855006 T PL 17855006T PL 3502105 T3 PL3502105 T3 PL 3502105T3
Authority
PL
Poland
Prior art keywords
compound
production
application
pharmaceutical composition
composition containing
Prior art date
Application number
PL17855006T
Other languages
English (en)
Polish (pl)
Inventor
Congxin Liang
Lihua Xie
Original Assignee
Equinox Sciences, Llc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Equinox Sciences, Llc. filed Critical Equinox Sciences, Llc.
Publication of PL3502105T3 publication Critical patent/PL3502105T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL17855006T 2016-09-29 2017-09-29 Postać polimorficzna związku stanowiącego inhibitor kinazy, zawierająca ją kompozycja farmaceutyczna oraz sposób jej wytwarzania i jej zastosowanie PL3502105T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610866253 2016-09-29
EP17855006.7A EP3502105B8 (en) 2016-09-29 2017-09-29 Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
PCT/CN2017/104506 WO2018059556A1 (zh) 2016-09-29 2017-09-29 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用

Publications (1)

Publication Number Publication Date
PL3502105T3 true PL3502105T3 (pl) 2022-07-11

Family

ID=61763329

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17855006T PL3502105T3 (pl) 2016-09-29 2017-09-29 Postać polimorficzna związku stanowiącego inhibitor kinazy, zawierająca ją kompozycja farmaceutyczna oraz sposób jej wytwarzania i jej zastosowanie

Country Status (17)

Country Link
US (3) US11053224B2 (https=)
EP (1) EP3502105B8 (https=)
JP (2) JP7253491B2 (https=)
KR (1) KR102289684B1 (https=)
CN (1) CN108884080B (https=)
AU (1) AU2017336889B2 (https=)
CA (2) CA3253105A1 (https=)
EA (1) EA201990688A1 (https=)
ES (1) ES2914294T3 (https=)
IL (2) IL265266B2 (https=)
MY (1) MY194364A (https=)
PH (1) PH12019500681A1 (https=)
PL (1) PL3502105T3 (https=)
SG (1) SG11201901962QA (https=)
TW (1) TWI647224B (https=)
WO (1) WO2018059556A1 (https=)
ZA (1) ZA201901717B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL265266B2 (en) * 2016-09-29 2024-08-01 Equinox Sciences Llc Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
EP3884929B1 (en) 2020-03-25 2023-06-14 Ocular Therapeutix, Inc. Ocular implant containing a tyrosine kinase inhibitor
EP4210682B1 (en) 2020-09-14 2026-03-25 EyePoint, Inc. Bioerodible ocular drug delivery insert and therapeutic method
WO2022197104A1 (ko) * 2021-03-16 2022-09-22 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물의 결정형
JP7138982B1 (ja) 2021-09-24 2022-09-20 東海物産株式会社 アンセリンの結晶及びその製造方法
WO2023173088A1 (en) 2022-03-11 2023-09-14 EyePoint Pharmaceuticals, Inc. Method of preventing age-related macular degeneration by administering an ocular drug delivery insert
CA3245209A1 (en) 2022-03-11 2023-09-14 EyePoint Pharmaceuticals, Inc. CONTINUOUS DOSAGE REGIMEN FOR THE TREATMENT OF AN EYE CONDITION
CA3245207A1 (en) 2022-03-11 2023-09-14 EyePoint Pharmaceuticals, Inc. TREATMENT METHOD FOR MOISTURE-RELATED MACULAR DEGENERATION
CN120897764A (zh) 2023-04-11 2025-11-04 视尔普斯眼科公司 包含阿西替尼多晶型物iv的眼部植入物
CN117143083B (zh) * 2023-08-30 2026-02-27 沈阳药科大学 VEGFR抑制剂Vorolanib的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003031438A1 (en) 2001-10-10 2003-04-17 Sugen, Inc. 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors
KR101507375B1 (ko) * 2006-09-15 2015-04-07 엑스커버리 홀딩 컴퍼니 엘엘씨 키나아제 억제제 화합물
US20110026367A1 (en) * 2007-05-07 2011-02-03 Baumer Electric Ag Acoustic Transducer
US20100256392A1 (en) * 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
KR20100135910A (ko) * 2008-04-16 2010-12-27 낫코 파마 리미티드 수니티닙 염기의 신규한 다형 형태
EP2292613B1 (en) * 2008-05-23 2015-09-30 Shanghai Institute of Pharmaceutical Industry Dihydroindolinone derivatives
EP2186809A1 (en) 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
EP2264027A1 (en) * 2009-05-27 2010-12-22 Ratiopharm GmbH Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
CN106928114B (zh) * 2015-12-31 2020-07-28 韶远科技(上海)有限公司 含有脲基的环状手性氨基类化合物及其可放大工艺和用途
IL265266B2 (en) * 2016-09-29 2024-08-01 Equinox Sciences Llc Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof

Also Published As

Publication number Publication date
TWI647224B (zh) 2019-01-11
IL265266B2 (en) 2024-08-01
MY194364A (en) 2022-11-29
AU2017336889A1 (en) 2019-04-11
SG11201901962QA (en) 2019-04-29
TW201815785A (zh) 2018-05-01
KR102289684B1 (ko) 2021-08-12
IL311631B1 (en) 2026-03-01
US20220356173A1 (en) 2022-11-10
US11053224B2 (en) 2021-07-06
JP2023082086A (ja) 2023-06-13
EP3502105B8 (en) 2022-06-01
IL265266A (en) 2019-05-30
EA201990688A1 (ru) 2019-08-30
US20190233403A1 (en) 2019-08-01
IL311631A (en) 2024-05-01
CN108884080A (zh) 2018-11-23
ES2914294T3 (es) 2022-06-08
HK1257194A1 (zh) 2019-10-18
EP3502105B1 (en) 2022-03-30
US20250188063A1 (en) 2025-06-12
JP7763203B2 (ja) 2025-10-31
WO2018059556A1 (zh) 2018-04-05
EP3502105A4 (en) 2020-04-15
CA3035124A1 (en) 2018-04-05
NZ751911A (en) 2024-07-26
AU2017336889B2 (en) 2021-11-25
CN108884080B (zh) 2020-10-27
JP7253491B2 (ja) 2023-04-06
US12209080B2 (en) 2025-01-28
JP2019529568A (ja) 2019-10-17
IL265266B1 (en) 2024-04-01
KR20190039823A (ko) 2019-04-15
CA3253105A1 (en) 2025-07-08
EP3502105A1 (en) 2019-06-26
PH12019500681A1 (en) 2019-11-25
BR112019006023A2 (pt) 2019-06-18
CA3035124C (en) 2025-11-18
ZA201901717B (en) 2019-11-27

Similar Documents

Publication Publication Date Title
PL3502105T3 (pl) Postać polimorficzna związku stanowiącego inhibitor kinazy, zawierająca ją kompozycja farmaceutyczna oraz sposób jej wytwarzania i jej zastosowanie
CY2024003I2 (el) Ενωσεις χρησιμες ως αναστολεις κινασης
IL282801A (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
LT3710446T (lt) Junginiai, naudingi cdk7 slopinimui
KR102609396B9 (ko) Ldha의 발현을 억제하기 위한 방법 및 조성물
IL263163A (en) Pyridines are converted as inhibitors of dnmt1
MA47575A (fr) Composés inhibiteurs d'oga monocyclique
LT3661921T (lt) Selektyvūs nlrp3 inflamasomos inhibitoriai
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
MA47576A (fr) Composés inhibiteurs d'oga bicyclique
DK3442947T3 (da) Aminsubstituerede aryl- eller heteroarylforbindelser som ehmt1- og ehmt2-hæmmere
DK3442980T3 (da) Heterocykliske forbindelser som ret-kinase-hæmmere
HUE057801T2 (hu) Aminotriazolopiridinek mint kináz inhibitorok
DK3312177T3 (da) Tricyklisk derivatforbindelse, fremgangsmåde til at fremstille samme og farmaceutisk sammensætning omfattende samme
DK3298002T3 (da) Heterocykliske amider som kinasehæmmere
HUE050842T2 (hu) Janus-kináz inhibitor
PL3322588T3 (pl) Rura wielowarstwowa i sposób jej wytwarzania
LT3652491T (lt) Produkto liofilizavimo būdas
HUE049502T2 (hu) Policiklusos vegyületek mint bruton-tirozin-kináz inhibitorok
HUE058292T2 (hu) Aminoimidazopiridazinok mint kináz inhibitorok
HUE049606T2 (hu) Eljárás flavonoid inklúziós vegyületek elõállítására
DK3390407T3 (da) Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser
EP3556758A4 (en) CDK4 / 6-INHIBITOR
DK3890828T3 (da) Heteroaromatiske forbindelser som vanin-hæmmere
IL269695A (en) Compounds useful as inhibitors of alcat 1